These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19306512)

  • 1. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer.
    Lindholm P; Lapela M; Någren K; Lehikoinen P; Minn H; Jyrkkiö S
    Nucl Med Commun; 2009 Jan; 30(1):30-6. PubMed ID: 19306512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.
    Pujara AC; Raad RA; Ponzo F; Wassong C; Babb JS; Moy L; Melsaether AN
    Breast J; 2016 May; 22(3):264-73. PubMed ID: 26843433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer.
    Huovinen R; Leskinen-Kallio S; Någren K; Lehikoinen P; Ruotsalainen U; Teräs M
    Br J Cancer; 1993 Apr; 67(4):787-91. PubMed ID: 8471437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
    Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
    J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?
    Jansson T; Westlin JE; Ahlström H; Lilja A; Långström B; Bergh J
    J Clin Oncol; 1995 Jun; 13(6):1470-7. PubMed ID: 7751894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography.
    Nuutinen J; Jyrkkiö S; Lehikoinen P; Lindholm P; Minn H
    Radiother Oncol; 1999 Sep; 52(3):225-32. PubMed ID: 10580868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction.
    Leskinen-Kallio S; Någren K; Lehikoinen P; Ruotsalainen U; Joensuu H
    Br J Cancer; 1991 Dec; 64(6):1121-4. PubMed ID: 1662533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and [11C]methionine.
    Lindholm P; Leskinen-Kallio S; Grénman R; Lehikoinen P; Någren K; Teräs M; Ruotsalainen U; Joensuu H
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):787-94. PubMed ID: 7790265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients.
    Huyge V; Garcia C; Alexiou J; Ameye L; Vanderlinden B; Lemort M; Bergmann P; Awada A; Body JJ; Flamen P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):818-27. PubMed ID: 20554438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
    Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH
    Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
    Shreve PD; Grossman HB; Gross MD; Wahl RL
    Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.
    De Giorgi U; Mego M; Rohren EM; Liu P; Handy BC; Reuben JM; Macapinlac HA; Hortobagyi GN; Cristofanilli M; Ueno NT
    J Nucl Med; 2010 Aug; 51(8):1213-8. PubMed ID: 20660382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
    Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I
    J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
    Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
    Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.